Roger Echols
Impact in
- Molecular Medicine top 0.05%
- Antibiotic Resistance in Bacteria
- Applied Microbiology and Biotechnology top 0.05%
- Antibiotic Use and Resistance
Papers in
- Pharmacology 71
- Antibiotics Pharmacokinetics and Efficacy 70
-
- Antibiotic Resistance in Bacteria 61
- Co-authors
- Yoshinori Yamano (33 shared papers)Masakatsu Tsuji (17 shared papers)Tsutae Den Nagata (18 shared papers)Mari Ariyasu (16 shared papers)Meredith Hackel (15 shared papers)Daniel F. Sahm (11 shared papers)Simon Portsmouth (15 shared papers)Steven F. Kowalsky (11 shared papers)
- Journals
- Open Forum Infectious Diseases (34 papers)Antimicrobial Agents and Chemotherapy (18 papers)Clinical Infectious Diseases (9 papers)Journal of Antimicrobial Chemotherapy (9 papers)The Pediatric Infectious Disease Journal (7 papers)
- Partner nations
- United StatesJapanCanada
In The Last Decade
Roger Echols
132 papers receiving 5.5k citations
Roger Echols's Hit Papers
Peers
Comparison fields: 5 of 115
- Molecular Medicine 2.8k
- Applied Microbiology and Biotechnology 967
- Pharmacology 2.2k
- Endocrinology 504
- Epidemiology 1.6k
Countries citing papers authored by Roger Echols
This map shows the geographic impact of Roger Echols's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Roger Echols with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Roger Echols more than expected).
Fields of papers citing papers by Roger Echols
This network shows the impact of papers produced by Roger Echols. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Roger Echols. The network helps show where Roger Echols may publish in the future.
Co-authors
The 25 scholars most cited alongside Roger Echols, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 132 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial Hit paper breakdown → | 2020 | 588 |
| 2 | Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia (APEKS-NP): a randomised, double-blind, phase 3, non-inferiority trial Hit paper breakdown → | 2020 | 338 |
| 3 | Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by Gram-negative uropathogens: a phase 2, randomised, double-blind, non-inferiority trial Hit paper breakdown → | 2018 | 324 |
| 4 | 1998 | 201 | |
| 5 | 2017 | 192 | |
| 6 | 1996 | 173 | |
| 7 | 2017 | 165 | |
| 8 | 2018 | 163 | |
| 9 | 2017 | 143 | |
| 10 | 1999 | 133 | |
| 11 | 2018 | 129 | |
| 12 | 1991 | 126 | |
| 13 | 1992 | 125 | |
| 14 | A trial comparing low-dose, short-course ciprofloxacin and standard 7 day therapy with co-trimoxazole or nitrofurantoin in the treatment of uncomplicated urinary tract infection. | 1999 | 94 |
| 15 | 2019 | 91 | |
| 16 | 2017 | 91 | |
| 17 | 2017 | 91 | |
| 18 | 2016 | 89 | |
| 19 | 2019 | 88 | |
| 20 | 1986 | 87 |
About Roger Echols
Roger Echols is a scholar working on Pharmacology, Molecular Medicine, Epidemiology, Applied Microbiology and Biotechnology and Pulmonary and Respiratory Medicine, having authored 132 papers that have together received 5.8k indexed citations. Recurring topics across this work include Antibiotics Pharmacokinetics and Efficacy (70 papers), Antibiotic Resistance in Bacteria (61 papers), Antibiotic Use and Resistance (29 papers), Pneumonia and Respiratory Infections (21 papers), Urinary Tract Infections Management (17 papers), Bacterial Identification and Susceptibility Testing (11 papers), Cystic Fibrosis Research Advances (7 papers) and Pharmaceutical studies and practices (6 papers). The work is most often cited by research in Molecular Medicine (2.8k citations), Applied Microbiology and Biotechnology (967 citations), Pharmacology (2.2k citations), Endocrinology (504 citations) and Epidemiology (1.6k citations). Roger Echols has collaborated with scholars based in United States, Japan and Canada. Frequent co-authors include Yoshinori Yamano, Masakatsu Tsuji, Tsutae Den Nagata, Mari Ariyasu, Meredith Hackel, Daniel F. Sahm, Simon Portsmouth, Steven F. Kowalsky, Takayuki Katsube and James A. Karlowsky. Their work appears in journals such as Open Forum Infectious Diseases, Antimicrobial Agents and Chemotherapy, Clinical Infectious Diseases, Journal of Antimicrobial Chemotherapy and The Pediatric Infectious Disease Journal.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.